V.K. Sevostyanov

V.K. Sevostyanov

Auto-generated profile, based on publicly available information

V.K. Sevostyanov


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
VSV.K. Sevostyanov
V.K. Sevostyanov
EZE.S. Zholobova
E.S. Zholobova
OBO.V. Baranova
O.V. Baranova
KPK.S. Poemshina
K.S. Poemshina
APA.I. Polukhina
A.I. Polukhina
SBS.L. Balashov
S.L. Balashov

1 January 2019 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
VSV.K. Sevostyanov
V.K. Sevostyanov
EZE.S. Zholobova
E.S. Zholobova
ANA.S. Novikov
A.S. Novikov
APA.I. Polukhina
A.I. Polukhina
SBS.L. Balashov
S.L. Balashov

10 August 2023 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
APAlbina Rinatovna Polishchuk
Albina Rinatovna Polishchuk
ARA.S. Romanova
A.S. Romanova
MKM.Sh. Khaider
M.Sh. Khaider
SBS.L. Balashov
S.L. Balashov
VSV.K. Sevostyanov
V.K. Sevostyanov
Вам открыли доступ к файлу. Отправлено с помощью Облако Mail.ru.

19 August 2022 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
VSV.K. Sevostyanov
V.K. Sevostyanov
PLP.S. Lototskaya
P.S. Lototskaya
NBN.V. Babich
N.V. Babich
DRD.D. Rassoha
D.D. Rassoha
ANA.S. Novikov
A.S. Novikov
MHMoscow Moscow City Center For Pediatric Rheumatology With The Morozov Children’s City Clinical Hospital
Moscow Moscow City Center For Pediatric Rheumatology With The Morozov Children’s City Clinical Hospital
The problem of the survival of various genetically engineered biological drugs (GEBD) is of a current scientific interest. A clear analysis of the reasons for the withdrawal coupled with the GEBD switching algorithmizing would allow developing of the individual treatment plans and monitoring of the patients. The objective of the study was to analyze the survival of genetically engineered biological therapy in children with juvenile idiopathic arthritis (JIA) through identifying the frequency and structure of cases of switching/cancellation of GEBD. Materials and methods: based on the data obtained from the Moscow registry of children with rheumatic diseases, an observational analytical cross-sectional study was conducted, including patients with JIA aged 0 to 17 years old living in Moscow, who had a history of episodes of switching or cancellation of GEBD. The study was conducted from January, 2015 to December, 2021. Results: 1220 patients (35.8% male/64.2% female) with JIA were included in the study. The median age of patients was 11.0 (8.0; 15.0) years. The total number of prescribing of GEBD of the first and subsequent lines was 589 episodes in 531 patients, of which 46 patients had 64 episodes of switching or cancellation of GEBD, which accounted for 10.9% of all cases of prescribing of GEBD. In the structure of the reasons for the therapy change the secondary failure accounted for 57.8%, the primary failure - 12.5%, intolerance - 10.9%, de novo uveitis - 9.4%. Cancellation of the drug therapy due to the achievement of remission was noted in 6.2% of cases. There are statistically significant differences in the duration of therapy depending on the reason for discontinuation or replacement of therapy (p<0.001). More often, patients were transferred to adalimumab (29.3%), and when adalimumab was canceled, to tocilizumab and golimumab. In the event of tocilizumab discontinuation, the majority of patients were switched to canakinumab drug therapy. Conclusion: the presented analysis is one of a few studies of such kind that were ever conducted in Russia; it requires further accumulation and analysis of data, including cases of discontinuation of the drug therapy, switching between the drugs, as well as the duration of therapy before the event that caused the change or discontinuation of the drug therapy happened.

1 January 2024 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
DRD.D. Rassokha
D.D. Rassokha
M1Moscow Children'S City Polyclinic No 120
Moscow Children'S City Polyclinic No 120
VSV.K. Sevostyanov
V.K. Sevostyanov
DUD.V. Usenko
D.V. Usenko
SES.I. Erdes
S.I. Erdes
MHMoscow Morozov Children'S City Clinical Hospital
Moscow Morozov Children'S City Clinical Hospital
Objective. To estimate the immunization coverage and vaccination rate of children (0-17 years of age inclusive) with juvenile idiopathic arthritis (JIA) for each individual infection according to the regional vaccination calendar in Moscow. Patients and Methods. An observational analytic cohort study including 753 patients with JIA and 753 healthy control children living in Moscow was conducted. Results. Patients with juvenile arthritis have lower immunization coverage than children without autoimmune disease; they are also less immunized compared with controls, but even the immunization rates of healthy children do not meet vaccination targets. Conclusion. The data from this study should be taken into account in order to optimize vaccine prophylaxis not only for patients with JIA but also for healthy children, as both groups require adjustment of the immunization schedule, approaches to immunoprophylaxis positioning and optimization of vaccination methods. Key words: vaccination, vaccine prophylaxis, immunization, epidemiology, juvenile arthritis

1 January 2024 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
DRD.D. Rassokha
D.D. Rassokha
M1Moscow Children'S City Polyclinic No 120
Moscow Children'S City Polyclinic No 120
VSV.K. Sevostyanov
V.K. Sevostyanov
ESErdes Svetlana
Erdes Svetlana
OPO.A. Pozdnyakova
O.A. Pozdnyakova
MHMoscow Morozov Children'S City Clinical Hospital
Moscow Morozov Children'S City Clinical Hospital
Objective. To assess the safety of vaccination in children (0-17 years inclusive) with juvenile idiopathic arthritis (JIA) in Moscow. Patients and methods. An observational analytical cross-sectional study including 400 patients with JIA was conducted. The minimum required sample size of the observational group was 328 patients. Results. Only 23.8% of patients (n = 95) continued to be vaccinated after the onset of JIA. The exacerbation of juvenile arthritis in patients after achieving remission was independent of continuation or discontinuation of vaccination (p = 0.139). Children with a complete vaccination schedule were less likely to have exacerbations than patients with an incomplete vaccination schedule (p = 0.044). Conclusion. Vaccination in children with JIA has been shown to be safe and does not lead to an increase in the number of exacerbations in the post-vaccination period. Further search for other factors that may influence the exacerbation of juvenile arthritis is required.